Qantas Raises Fuel Cost Forecast Amid Middle East Oil Crisis 
NiSource Signs Long-Term Energy Deals with Alphabet and Amazon to Power Indiana Data Centers 
Amazon in Advanced Talks to Acquire Globalstar in Starlink Rivalry Move 
Netflix Q2 Profit Warning Sends Shares Tumbling as Reed Hastings Exits 
KKR's $820M Investment Fuels Samsung SDS AI Expansion, Sending Group Shares Soaring 
Pentagon Taps Auto Giants to Supercharge U.S. Weapons Production 
Daikin Industries Stock Surges 14% After Elliott Investment Management Discloses Major Stake 
Hermès Q1 2026 Sales Miss Expectations Amid Iran War and China Slowdown 
Uber Bets Big on Autonomous Vehicles with $10 Billion Commitment 
Federal Judge Dismisses DOJ Lawsuit Attempting to Block Hawaii's Climate Case Against Oil Giants 
Samsung Races to Deliver Next-Gen HBM4E Memory Samples to Nvidia 
DEEPX Partners with Hyundai to Power Next-Gen AI Robots Ahead of IPO 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
ASML Raises 2026 Revenue Outlook as AI Chip Demand Surges 
Texas AG Investigates Lululemon Over "Forever Chemicals" in Activewear 
SK Hynix Shares Hit Record High Amid AI Memory Demand Surge 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
BOTHELL, Wash., April 06, 2016 -- Alder BioPharmaceuticals, Inc. (NASDAQ:ALDR), a clinical-stage biopharmaceutical company, announced today the pricing of an underwritten public offering of 5,376,344 shares of its common stock at a price to the public of $23.25 per share. In addition, Alder has granted the underwriters a 30-day option to purchase up to 806,451 additional shares of common stock at the public offering price. The offering is expected to close on April 12, 2016, subject to customary closing conditions.
J.P. Morgan Securities LLC, Leerink Partners LLC and Wells Fargo Securities, LLC are acting as joint book-running managers for the offering.
A shelf registration statement relating to the offered shares of common stock was filed with the Securities and Exchange Commission (SEC), and was effective on filing on June 2, 2015. A preliminary prospectus supplement and the accompanying prospectus relating to the offering have been filed with the SEC and are available on the SEC’s website, located at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to this offering may be obtained, when available, from J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by phone at 1-866-803-9204, or by email at [email protected]; from Leerink Partners LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, or by phone at 1-800-808-7525 ext. 6142, or by email at [email protected]; or from Wells Fargo Securities, LLC, Attention: Equity Syndicate Department, 375 Park Avenue, New York, New York 10152, or by phone at 1-800-326-5897, or by email at [email protected].
This press release shall not constitute an offer to sell or a solicitation of an offer to buy these securities nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Media Contacts: David Schull or Lena Evans Russo Partners (212) 845-4271 (212) 845-4262 [email protected] [email protected] Investor Relations Contacts: David Walsey Alder BioPharmaceuticals, Inc. (425) 408-8032 [email protected]
